Barclays Maintains Overweight on Fate Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Fate Therapeutics (NASDAQ:FATE) but has lowered the price target from $12 to $6.
August 10, 2023 | 11:25 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Fate Therapeutics but lowered the price target from $12 to $6.
The news directly pertains to Fate Therapeutics as Barclays has lowered the price target for the company's stock. This could potentially lead to a decrease in the stock price in the short term as it indicates that the analyst believes the stock is currently overvalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100